<DOC>
	<DOCNO>NCT02827162</DOCNO>
	<brief_summary>Primary objective : - To assess dengue vaccine efficacy varies across participant subgroup regard polymorphism human leukocyte antigen ( HLA ) alleles interest . - To assess association HLA allele , serotype-specific neutralization antibody titer summary neutralization measure vaccine placebo group . - To assess association polymorphism HLA alleles interest susceptibility Dengue fever Dengue Haemorrhagic fever . Secondary objective : - To assess whether dengue serotype-specific neutralizing antibody titer associate summary neutralization measure 28 day post-dose 3 related rate occurrence symptomatic Virologically-confirmed dengue infection post-dose 3 - To evaluate whether dengue serotype-specific neutralizing antibody associate summary neutralization measure 28 day post-dose 3 related level vaccine efficacy dengue virus post-dose 3 .</brief_summary>
	<brief_title>Association Host Genetics With Vaccine Efficacy Study Immune Correlates Risk From Tetravalent Dengue Vaccine</brief_title>
	<detailed_description>The enrolled population include , virologically-confirmed ( VC ) dengue case subject experience VC dengue infection ( control subject ) first Proof Concept efficacy study conduct Thailand Analyses correlate perform sample collect context first proof concept efficacy study . Sequencing dengue virus also do sample collect within context . Immunogenetic testing perform saliva sample collect study enrollment visit . No intervention vaccine provide administered part study .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject currently enrol , recently finish , CYD57 ( NCT01983553 ; longterm safety followup study first PoC efficacy study ) , include subject list provide Sponsor , without past experience virologically confirm dengue . For child 7 &lt; 18 year . Assent form ( AF ) sign date subject , informed consent form ( ICF ) sign dated parent another legally acceptable representative independent witness , per local Ethics Committee ( EC ) requirement . For subject â‰¥ 18 year . ICF sign date subject independent witness , per local EC requirement . Subject ( parent ( ) / legally acceptable representative subject &lt; 18 year ) able attend schedule visit comply study procedure . Any illness , opinion Investigator , might interfere study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Dengue Fever</keyword>
	<keyword>Dengue Haemorrhagic Fever</keyword>
	<keyword>Tetravalent Dengue Vaccine</keyword>
</DOC>